On August 6, 2020 WHO released their COVID-19 vaccine global access (COVAX) facility document to justify their “accelerated vaccine development and manufacture.” [1]
WHO, Gavi and CEPI launched the COVAX facility to ensure global equitable access to COVID-19 vaccines and end the acute phase of the pandemic by the end of 2021. [9]
“Developing a vaccine against COVID-19 is the most pressing challenge of our time” claiming the IMF estimated in April 14, 2020, that a vaccine [that didn’t exist] would “prevent the loss $375 Billion to the global economy every month”.
COVAX is the “vaccine” arm of the April 2020 United Nations collaborative ACT Accelerator
- Gavi launched the finance arm, COVAX AMC on June 4, 2020
- Australia’s Jane Halton, who is the Chair of CEPI is also the co-chair of COVAX. Australia has signed agreements. “In early 2020, CEPI raised US$2b to expand the number of vaccine candidates to increase the chances of success, and fund the clinical trials”.
- The COVAX Shareholders Council meetings began November 3, 2020 in Geneva. [10]
- COVAX coorinated vaccine roll out to to 92 low- and middle-income economies.
- COVAX began to take shape early 2020, and was sold based on the claim that “no one is safe, unless everyone is safe”, where “vaccines” are that saviour. [2]
- COVAX was led by GAVI [4, 5], CEPI and the WHO, alongside key delivery partner UNICEF
- Feb 22, 2023 – On behalf of COVAX partners WHO developed a No-Fault Compensation Program – the first and only global vaccine injury compensation mechanism
- Jan 31, 2021 the WHO “had to” generate a “tool” to encourage “acceptance and demand” for COVID-19 vaccines! as part of the Country Readiness and Delivery (CRD) workstream [3, 7, 8]
- January 2022 the COVID-19 Vaccine Delivery Partnership (CoVDP) was launched
- COVAX closed December 31, 2023 [6]